comparemela.com

Latest Breaking News On - Renfeng guo - Page 1 : comparemela.com

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

InflaRx N : Desired blocking activity (>90%) of C5a-induced neutrophil activation at disease relevant C5a levels 24 hours post administration for doses of 30 mg to 240 mg - Form 6-K -Today at 08:49 am

InflaRx (NASDAQ:IFRX) Sees Significant Drop in Short Interest

InflaRx (NASDAQ:IFRX – Get Rating) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 705,400 shares, a decrease of 26.3% from the April 30th total of 956,900 shares. Based on an average daily trading volume, of 2,410,000 shares, the short-interest […]

Viveon Health Acquisition (NYSE:VHAQ) vs InflaRx (NASDAQ:IFRX) Critical Survey

Viveon Health Acquisition (NYSE:VHAQ – Get Rating) and InflaRx (NASDAQ:IFRX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk. Earnings & Valuation This table compares Viveon Health Acquisition […]

InflaRx (NASDAQ:IFRX) Short Interest Up 933 4% in April

InflaRx (NASDAQ:IFRX – Get Rating) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,890,000 shares, an increase of 933.4% from the March 31st total of 182,900 shares. Based on an average trading volume of 2,300,000 shares, the days-to-cover ratio […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.